Join
Live feed
·
PRReleasevia Quantisnow
Telix Pharmaceuticals Limited logo

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
TLX· Telix Pharmaceuticals Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TLX (Telix Pharmaceuticals Limited) and more on Quantisnow.